In adults and children five years and up Benlysta can be administered by a medical professional through an IV (intravenous) infusion directly into the vein; adults can self-administer an injection ...

Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis Please see US Prescribing Information for Benlysta. This is the first FDA-approved ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

The FDA has expanded the approval of belimumab to include pediatric patients 5 to 17 years of age with active lupus nephritis. The Food and Drug Administration (FDA) has expanded the approval of ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

BENLYSTA is indicated for patients aged ≥5 with active systemic lupus erythematosus (SLE) or active lupus nephritis who are receiving standard therapy. BENLYSTA is not recommended in patients with ...